摘要
目的:探讨伴有血糖增高的精神分裂症患者换用齐拉西酮或阿立哌唑治疗后血糖水平的变化。方法:对40例伴有血糖增高的精神分裂症患者随机分为齐拉西酮组和阿立哌唑组各20例,分别换用齐拉西酮和阿立哌唑治疗,观察12周。于换药前后检测空腹及餐后2h血糖;同时采用阳性与阴性症状量表(PANSS)评定疗效及对血糖的影响。结果:换药12周后,两组血糖水平降低占80%;血糖水平降至正常占72.5%;血糖水平变化不明显占20%。两组间比较,差异无统计学意义(t=0.625,P≥0.05)。换药前后两组精神症状变化不明显(t=0.106,0.433;P均≥0.05)。结论:伴血糖增高的精神分裂症患者换用齐拉西酮或阿立哌唑治疗后血糖水平明显降低。
Objective：To explore the influence of ziprasidone versus aripirazole on glucose in the treatment of schizophrenia with hyperglycemia. Method：A total of 40 patients with hyperglycemia schizophrenia were randomized into ziprasidone group（n=20） or aripirazole group（n=20）.One group was changed with ziprasidone and the other with aripirazole for 12 weeks.Fasting blood glucose and 2 hours glucose were measured before and after replacement drugs.At the same time,positive and negative syndrome scale （PANSS） were used to ecaluate efficacy. Results：At the 12th weekend,blood glucose levels decreased among 80% patients and the levels did not change significantly among 20% patients;72.5% patients reached the normal level,There were no significant differences between the two groups（t=0.625,P≥0.05）.Compared with the baseline,scores of PANSS in both groups showed no significanty changes（t=0.106,0.433;P≥0.05）. Conclusion： Ziprasidone and aripiprazole both have higher efficacy in reducing glucose in schizophrenia patients with hyperglycemia.
出处
《临床精神医学杂志》
2013年第2期115-116,共2页
Journal of Clinical Psychiatry
关键词
精神分裂症
齐拉西酮
阿立哌唑
血糖
schizophrenia
ziprasidone
aripiprazole
blood glucose
